Oncopeptides AB (OSTO:ONCO) EPS (Basic): kr-0.88 (TTM As of Mar. 2026)


OSTO:ONCO Oncopeptides AB OSTO:ONCO
35 GF Score
Price kr1.61
GF Value kr4.21
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Oncopeptides AB EPS (Basic)?

Oncopeptides AB OSTO:ONCO -0.98% 35 EPS (Basic) is kr-0.88 as of Mar. 2026. GuruFocus rates OSTO:ONCO with a GF Score™ of 35/100 and a GF Value™ of kr4.21 (Possible Value Trap). The stock has 3 warning signs investors should review.

Oncopeptides AB's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was kr-0.12. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.88.

Oncopeptides AB's EPS (Diluted) for the three months ended in Mar. 2026 was kr-0.12. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.88.

Oncopeptides AB's EPS without NRI for the three months ended in Mar. 2026 was kr-0.12. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.88.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Oncopeptides AB  (OSTO:ONCO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Oncopeptides AB EPS (Basic) Related Terms

Oncopeptides AB EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Oncopeptides AB's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncopeptides AB EPS (Basic) Chart

Oncopeptides AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.04 -2.61 -2.46 -1.61 -1.04

Oncopeptides AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.27 -0.26 -0.24 -0.12
OSTO:ONCO
35GF Score
Oncopeptides AB OSTO:ONCO
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncopeptides AB EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Oncopeptides AB's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-249.585-0)/240.551
=-1.04

Oncopeptides AB's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-32.185-0)/268.208
=-0.12

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of kr-0.88 mean?
Oncopeptides AB (OSTO:ONCO) has a EPS (Basic) of kr-0.88 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Oncopeptides AB and its competitors.
Is Oncopeptides AB's EPS (Basic) too high?
Oncopeptides AB's current EPS (Basic) is kr-0.88. Overall, Oncopeptides AB has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's EPS (Basic) compare to VRTX and REGN?
Oncopeptides AB's EPS (Basic) of kr-0.88 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Oncopeptides AB and its competitors. Oncopeptides AB's current EPS (Basic) is kr-0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (OSTO:ONCO) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.21, compared to a current price of kr1.61 — trading 61.7% below its estimated fair value. The current EPS (Basic) is kr-0.88. Oncopeptides AB's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Oncopeptides AB (OSTO:ONCO), the current EPS (Basic) is kr-0.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncopeptides AB (OSTO:ONCO) Overvalued in 2026?

Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued. The current stock price of kr1.61 is trading 61.7% below its estimated GF Value™ of kr4.21. GuruFocus considers Oncopeptides AB to be Possible Value Trap.

Key valuation signals for OSTO:ONCO:

  • EPS (Basic): kr-0.88
  • GF Value™: kr4.21 vs. price of kr1.61 (61.7% below fair value)
  • GF Score™: 35/100 with 3 warning signs

No single metric tells the full story. See the OSTO:ONCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncopeptides AB Business Description

Other Exchanges ONCOs:UK0RN4:UKOND:Germany
Address Luntmakargatan 46, Stockholm, SWE, SE-111 37
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
35GF Score

Get the complete analysis for OSTO:ONCO

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.61
Price
kr4.21
GF Value